Pulmonary arterial hypertension (PAH) is a vascular remodeling disease that pathologically increases pulmonary vascular resistance. Ultimately, this leads to right ventricular failure and ...

BMPER attenuated PI3K/AKT signaling and suppressed BMP4-driven smooth muscle activation in models of PAH. BMPER overexpression mitigated the vascular remodeling that characterizes pulmonary arterial ...

Three Phase 1 studies support once-daily inhaled administration of mosliciguat with no evidence of serious systemic side ...

The final, formatted version of the article will be published soon. Purpose of Review: Pulmonary arterial hypertension (PAH) is a progressive clinical syndrome characterized by pulmonary vascular ...

Scientists have found a novel way that includes a new lab-grown material that could help slow and even reverse some of the ...

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic ...

Panelists discuss how pulmonary arterial hypertension diagnosis requires comprehensive evaluation including right heart catheterization to confirm hemodynamic criteria, with normal mean PA ...

BofA raises Insmed price target to $109 after strong TPIP data and flags FDA decision on brensocatib as a near-term share catalyst.

SCOTUS ruling targets 'reverse discrimination' in the workplace | Here's what that means. Posted: June 5, 2025 | Last updated: June 6, 2025. Here's what the Supreme Court had to say.

Novel truncated RNAs from jumping DNA encode reverse transcriptases in aging human brain by Sanford-Burnham Prebys edited by Stephanie Baum , reviewed by Robert Egan ...